Abstract

Enterococcus spp. are one of the most frequent producers of bacteriocins (enterocins), which provides them with an advantage to compete in their natural environment, which is the gut of humans and many animals. The enterocins’ activity against microorganisms from different phylogenetic groups has raised interest in Enterococcus spp. in different contexts throughout the last decades, especially in the food industry. Nevertheless, some species can also cause opportunistic life-threatening infections and are frequently multidrug-resistant (MDR). Vancomycin-resistant Enterococcus (VRE), in particular, are an ongoing global challenge given the lack of therapeutic options. In this scenario, bacteriocins can offer a potential solution to this persistent threat, either alone or in combination with other antimicrobials. There are a handful of studies that demonstrate the advantages and applications of bacteriocins, especially against VRE. The purpose of this review is to present a current standpoint about the dual role of Enterococcus spp., from important producers to targets needed to be controlled, and the crucial role that enterocins may have in the expansion of enterococcal populations. Classification and distribution of enterocins, the current knowledge about the bacteriocinome of clinical enterococci, and the challenges of bacteriocin use in the fight against VRE infections are particularly detailed.

Highlights

  • The number of bacterial strains resistant to antibiotics has increased radically, making antimicrobial resistance (AMR) a major global health emergency of the 21st century [1,2].Currently, AMR infections are responsible for at least 700,000 deaths each year worldwide

  • An emerging area of interest is the development of very-narrow-spectrum or species-specific antimicrobials, where the goal is to target only the microbe(s) that are causing infection, limiting the selection for resistance and dysbiosis commonly induced in the coexisting beneficial microbiota by broad-spectrum antimicrobials [9]. Such an approach can include the use of bacteriocins, which are a subset of the antimicrobial peptides (AMPs) that are produced by bacteria [10]

  • Vancomycin-resistant E. faecium (VREfm) stands as one of the most common causes of hard-to-treat hospital infections and, due to lack of therapeutic options, is recognized by World Health Organization (WHO) as a priority pathogen urgently requiring new antimicrobials [20], with the use of next-generation probiotics derived from the gut microbiota and bacteriocins as alternatives proposed [21]

Read more

Summary

A Double-Edged Sword in the Antimicrobial Resistance

Citation: Almeida-Santos, A.C.; Novais, C.; Peixe, L.; Freitas, A.R. Enterococcus spp. as a Producer and Target of Bacteriocins: A DoubleEdged Sword in the Antimicrobial Associate Laboratory i4HB, Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal TOXRUN–Toxicology Research Unit, Department of Sciences, University Institute of Health Sciences, CESPU, CRL, 4585-116 Gandra, Portugal

Introduction
Diversity of Bacteriocins Produced by Enterococci
Classification and Origin of Known Enterocins
Class I—Lantibiotics
Class II—Non-Lantibiotics
Class II—Other Bacteriocins
Class III—Bacteriolysins
Diversity of Enterocins in Clinical Enterococci
Use of Bacteriocins to Fight against VRE Human Infections
Challenges of Bacteriocin Use
Findings
Future Perspectives
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call